Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Non Operating Income for 4 consecutive years, with -$1.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non Operating Income rose 65.21% year-over-year to -$1.4 million, compared with a TTM value of $8.8 million through Dec 2024, up 313.8%, and an annual FY2025 reading of $62.2 million, up 606.71% over the prior year.
  • Non Operating Income was -$1.4 million for Q4 2024 at SAB Biotherapeutics, down from $959956.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.8 million in Q1 2022 and bottomed at -$4.0 million in Q4 2023.
  • Average Non Operating Income over 4 years is $930917.2, with a median of $134397.0 recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 36168.02% in 2023, then soared 13108.14% in 2024.
  • Year by year, Non Operating Income stood at -$450448.0 in 2021, then surged by 102.45% to $11043.0 in 2022, then plummeted by 36168.02% to -$4.0 million in 2023, then soared by 65.21% to -$1.4 million in 2024.
  • Business Quant data shows Non Operating Income for SABS at -$1.4 million in Q4 2024, $959956.0 in Q3 2024, and $2.9 million in Q2 2024.